Clinical Report: A Two-Biomarker Signal for Alzheimer’s Disease
Overview
A prospective cohort study indicates that combining plasma biomarkers p-tau217 and eMTBR-tau243 can enhance the identification of established Alzheimer's disease and predict cognitive decline. This dual biomarker approach demonstrates high accuracy in distinguishing patients with significant tau pathology.
Background
Alzheimer's disease (AD) is a leading cause of dementia, affecting millions globally. Accurate diagnosis and staging of AD are critical for effective management and treatment strategies. Recent advancements in blood-based biomarkers offer promising avenues for improving diagnostic precision and understanding disease progression.
Data Highlights
| Biomarker | Accuracy | Positive Predictive Value |
|---|---|---|
| Combined p-tau217 and eMTBR-tau243 | 81% | 84% |
| eMTBR-tau243 for high tau pathology | 87% | N/A |
Key Findings
- The combination of p-tau217 and eMTBR-tau243 improves identification of established Alzheimer's disease.
- Patients with positive p-tau217 results showed 81% accuracy and 84% positive predictive value when eMTBR-tau243 was added.
- eMTBR-tau243 demonstrated 87% accuracy in identifying patients with high tau pathology.
- Higher levels of eMTBR-tau243 were associated with greater tau accumulation and cognitive decline.
- The study supports a two-step testing strategy for better diagnostic precision.
Clinical Implications
The findings suggest that integrating plasma biomarkers into clinical practice can enhance diagnostic accuracy for Alzheimer's disease. Clinicians may consider using a two-step approach to differentiate between asymptomatic amyloid pathology and clinically significant Alzheimer's disease.
Conclusion
The study underscores the potential of a dual biomarker strategy in improving the diagnosis and understanding of Alzheimer's disease pathology, warranting further research in diverse clinical settings.
Related Resources & Content
- Brain, Oxford University Press, 2023 -- Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder
- Retinal Physician, 2024 -- Retinal Biomarkers for Alzheimer Disease
- Acta Neuropathologica, 2014 -- A Biochip Utilizing Platelet Proteins Enables Rapid Identification of Alzheimer’s Disease-Specific Phenotypes
- Acta Neuropathologica, 2022 -- Plasma Biomarkers Associated with Alzheimer’s Disease: Links to Neuropathological Changes and Cognitive Decline
- Clinical practice guideline for blood‐based biomarkers in the diagnostic workup of Alzheimer’s disease within specialized care settings: A report from the Alzheimer's Association - PMC
- FDA, 2025 -- FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease
- Nature Medicine, 2025 -- Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
- Clinical practice guideline for blood‐based biomarkers in the diagnostic workup of Alzheimer’s disease within specialized care settings: A report from the Alzheimer's Association - PMC
- FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease | FDA
- Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease | Nature Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
